MS Archives - Medical Cannabis Awareness New Zealand

Germany allows MS patient to grow cannabis in unprecedented case

Posted on October 4, 2016 by admin

Germany's Federal Institute for Drugs and Medical Devices (BfArM) confirmed on Sunday that the patient from Mannheim, southwestern Germany, will be allowed to grow a maximum of 130 cannabis plants a year in his bathroom. The cannabis is strictly for personal use, a spokesperson said.BfArM had previously rejected requests to home-grow cannabis. There are currently more than 900 patients in Germ...
Read More

One News: Pressure Mounts on Pharmac to fund Sativex

Posted on June 6, 2016July 25, 2016 by admin

Ryan Boswell reports on the progress of Jamie O'mara and asks The Epilepsy Association and MS Society on there thoughts regarding Sativex funding and Pharmac. To help Jamie and others with the costs of Sativex please consider donating to our Registered Charity.
Read More

#MC410 Sativex for Warren Edney

Posted on June 2, 2016July 25, 2016 by admin

Warren was diagnosed with Multiple Sclerosis (MS) in May 2013. Warren was just 41 years old at the time. MS causes damage to nerves in the body. Nerves in the brain and spine send messages to parts of the body. These messages help with bodily functions e.g. Flexing and straightening muscles; for bladder function; for the mechanics of speech etc.“I knew what MS was because my mother had MS. Th...
Read More

One News: ‘How much pain do I need to be in?’ MS sufferer pleads for funding of medical cannabis

Posted on May 30, 2016July 25, 2016 by admin

Sickness beneficiary Warren Edney, who suffers immensely from a rapidly progressing form of MS, on his need for Medical Cannabis, to support Warren, and others like him, please consider donating to him on our give a little page.
Read More

Nelson Mail: Takaka woman’s use of cannabis to treat MS ‘topical’

Posted on March 1, 2016July 31, 2016 by Shane Le Brun

A Nelson District Court judge struggled to find an appropriate sentence for a woman who cultivated cannabis to help treat her multiple sclerosis.Fiona Porter, 45, told the court on Monday that she grew cannabis for personal medicinal use after medication prescribed to treat her multiple sclerosis left her unable to see, walk or speak properly at times.Police found 11 mature cannabis plants...
Read More

#MC410 2 weeks on Sativex, initial thoughts of Dr Hu

Posted on February 24, 2016July 26, 2016 by Shane Le Brun

I would like to share my initial thoughts after my first two weeks on Sativex, the medicinal cannabis spray that is legally available in New Zealand. I waited (saved) for 6 months after it was approved for my condition which is Primary Progressive Multiple Sclerosis, C.O.P.D and arthritis, and I must admit I began with some trepidation. I had just forked out $1200.00 which we could use on othe...
Read More

Sativex funding petition delivered today.

Posted on February 8, 2016August 8, 2016 by Shane Le Brun

Today Sushila Butt delivered a petition to David Clendon, Green MP for Kaitaia, with 6125 signatures on it. The petition was for the funding of Sativex for MS and also for life threatening seizures. Sushila Butt conducted this petition upon experiencing a terrific turn around in her daughters seizures, where her life was at serious risk, but with a low dose of Sativex ( 5 sprays a day) her s...
Read More

Evaluating Sativex® in Neuropathic Pain Management: A Clinical and Neurophysiological Assessment in Multiple Sclerosis.

Posted on February 6, 2016July 31, 2016 by Shane Le Brun

Authors: Russo M, Naro A, Leo A, Sessa E, D'Aleo G, Bramanti P, Calabrò RS. AbstractOBJECTIVE : The aim of our study was to better investigate the role of Sativex® in improving pain in multiple sclerosis (MS) patients by means of either clinical or neurophysiological assessment. SETTING: Pain is a common symptom of MS, affecting up to 70% of patients. Pain treatment is often unsatisfactor...
Read More

Cost-effectiveness of Sativex in multiple sclerosis spasticity: new data and application to Italy.

Posted on January 9, 2016August 8, 2016 by Shane Le Brun

Authors Slof J, Ruiz L, Vila C.Abstract;Multiple sclerosis (MS) is a chronic progressive disease that carries a high socioeconomic burden. Spasticity (rigidity and spasms) is common in MS and contributes to MS-related disability. This study aims to evaluate the cost-effectiveness of Sativex(®) (9-delta-tetrahydrocannabinol plus cannabidiol oromucosal spray) when used as add-on therapy fo...
Read More

Walking improvements with nabiximols in patients with multiple sclerosis.

Posted on January 4, 2016August 1, 2016 by Shane Le Brun

Authors Coghe G, Pau M, Corona F, Frau J, Lorefice L, Fenu G, Spinicci G, Mamusa E, Musu L, Massole S Massa R, Marrosu MG, Cocco E.Abstract: Recently, nabiximols was approved as a treatment in MS spasticity. Data leading to approval and clinical use of nabiximols, although widely recognised, are based on subjective scales. Movement analysis procedures would obtain more detailed data about the...
Read More